After Hikma: Proving Inducement Without a Smoking Gun

The U.S. Supreme Court’s decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., 608 U.S. ___ (2026), is not simply another skinny-label case. For patent litigators, its larger significance is evidentiary. The decision forces a sharper distinction between three concepts that often blur together in induced-infringement cases: knowledge of infringement, commercial benefit from infringement, and affirmative conduct that encourages infringement.

Only the third proves inducement.

That distinction should change how inducement claims are investigated, pleaded, and discovered. A plaintiff can no longer expect to survive by alleging that the defendant knew how the market would use the product, that infringement was predictable, and that the defendant’s public statements could be understood as encouragement. The question is more disciplined: did the defendant take affirmative steps that made the infringing use more than merely foreseeable?

That does not mean plaintiffs need a document saying “go infringe the patent.” Hikma does not impose a smoking-gun requirement. The Court recognized that inducement can be implicit. But the implicit message still must be affirmative, clear to the relevant audience, and tied to the infringing conduct. That is where the litigation work now sits.

The Real Holding for Litigators

The Federal Circuit’s error, as the Supreme Court saw it, was framing the question from the recipient’s side: could a physician read the challenged statements as encouragement to infringe? The Supreme Court reframed the inquiry from the defendant’s side: did the defendant actively encourage the infringing use?

That shift matters. It is not enough that a doctor, customer, engineer, pharmacist, integrator, or end user could draw an infringing inference from ambiguous materials. The plaintiff must connect the defendant’s conduct to a purposeful effort to bring about the patented use.

In practical terms, Hikma moves inducement away from “how might the market understand this?” and toward “what was the defendant trying to cause, and what did it do to cause it?” That is a more demanding evidentiary question, but not an impossible one.

Do Not Confuse Knowledge, Intent, and Active Steps

The first post-Hikma discipline is conceptual. Patent litigators should separate three showings at the outset. Knowledge asks whether the defendant knew about the patent and knew the induced acts would infringe. Commercial intent asks whether the defendant wanted sales that may have included infringing uses. Active inducement asks whether the defendant affirmatively encouraged another actor to perform the patented method.

The first two may support the third, but they do not substitute for it. A defendant may know that customers will infringe. It may forecast revenue from infringing uses. It may even be pleased when those uses occur. But if the record shows only sales into a market where infringement is likely, Hikma gives the defendant a strong answer: foreseeability is not inducement.

The plaintiff needs conduct. More precisely, the plaintiff needs defendant-originated conduct that points the relevant audience toward the infringing use.

The Discovery Problem: The Best Evidence Is Usually Internal

The difficult procedural problem is obvious. The evidence most likely to prove affirmative encouragement is often internal: launch plans, sales training, account strategy, field instructions, customer targeting, call notes, reimbursement strategy, and “what we can and cannot say” guidance. But the plaintiff must plead enough before getting discovery.

That makes the use of public materials more important, but also more dangerous. Public statements can be useful pleading hooks. They can show what the defendant put into the market, how it described the product, and which audiences it appeared to target. But after Hikma, public materials that are vague, required, investor-facing, or consistent with ordinary product distribution will rarely carry the case alone.

The pleading task is therefore not to overstate the public materials. It is to use them to allege a coherent inducement path: a specific patented use, a relevant audience, a defendant message or course of conduct, and a reason the conduct is better understood as encouragement than as ordinary commerce.

A complaint that says “the defendant’s statements could lead users to infringe” is vulnerable. A complaint that says “the defendant targeted a user group defined by the infringing use, gave that group materials keyed to claim limitations, trained its personnel to push that use while avoiding explicit restricted language, and measured success by conversion of that use” is materially different.

Start Discovery With the Claim, Not the Product

Inducement discovery should begin with the asserted method claim. That sounds obvious. It often is not how discovery is actually framed. The accused product may be capable of many uses. Some infringe; some do not. Discovery requests that ask broadly for “marketing of the accused product” invite overproduction, fights over burden, and a record cluttered with lawful promotion. Worse, they may obscure the missing link: promotion of the infringing method.

The better approach is to build a discovery plan around the claim limitations. If the claim requires a particular patient population, dose, diagnostic marker, co-administered therapy, software configuration, sequence of steps, operating condition, or downstream application, discovery should be keyed to that requirement. The working chart should not merely map the product to the claim. It should map the alleged inducement evidence to the claim.

That chart should drive the first wave of document requests, interrogatories, 30(b)(6) topics, and third-party subpoenas. It also gives the court a practical way to see why the discovery is proportional.

Sequence Discovery to Avoid Chasing Noise

A post-Hikma discovery plan should be sequenced. The goal is to move quickly from general suspicion to evidence that either supports or defeats active inducement.

The first phase should establish the lawful baseline. What did the defendant have to say? What was required by regulation, contract, industry standard, platform rule, customer specification, or technical compatibility? Who drafted the challenged language? Could it have been changed? Was it carried over from a required source? Was it reviewed by regulatory or legal personnel for a non-promotional reason?

This matters because Hikma treats obvious lawful explanations seriously. A plaintiff that cannot separate required conduct from voluntary promotion will struggle.

The second phase should target discretionary commercial conduct. This includes sales training, marketing strategy, launch decks, account plans, field guidance, call scripts, CRM entries, customer presentations, reimbursement materials, formulary submissions, distributor instructions, technical-support guidance, implementation materials, and internal discussions of how to position the product.

This is where inducement evidence is most likely to appear. Not necessarily as a blunt instruction, but as a practical sales or implementation strategy: do not say the forbidden thing; say this instead. Target these accounts. Use this study. Discuss this outcome. Position against the branded or patented use. Capture this customer segment.

The third phase should test recipient-side proof. Did the relevant audience receive the message? Was the audience capable of performing or causing the infringing steps? Did the message matter? Did call notes, emails, meeting records, support tickets, or customer testimony connect the defendant’s conduct to the accused use?

This sequencing is important. Recipient discovery without a defendant-originated inducement theory can become unfocused. Internal discovery without a claim-limitation map can become a fishing expedition. Baseline discovery without commercial follow-through can leave the plaintiff proving only that the defendant acted lawfully.

The Most Important Evidence May Be the “Deniability” Document

In real cases, sophisticated defendants rarely say “induce infringement.” The more valuable evidence may be the document that teaches personnel how to approach the infringing use without saying the quiet part directly. Examples include:

• Do not mention the patented indication, but discuss the same patient population.

• Do not claim compatibility with the patented configuration, but ask whether the customer is using that configuration.

• Do not promote the restricted method, but provide the study or outcome data associated with it.

• Do not use the competitor’s patented terminology, but position the product for the same application.

• Do not answer directly in writing; schedule a call.

Those documents can matter because they show both awareness and a course of conduct designed to influence the relevant actor. They also help answer the defendant’s likely argument that any infringing use resulted from customer choice rather than defendant encouragement.

The point is not that coded language always proves inducement. It does not. The point is that inducement may be implicit, and the best implicit-inducement evidence often appears in the gap between formal compliance and practical sales behavior.

Audience Is Not a Formality

After Hikma, audience is not just context. It is part of the evidentiary bridge.

Investor-facing statements, generalized product announcements, and broad website descriptions may be too attenuated if the relevant infringer is a physician, pharmacist, engineer, installer, developer, or end user. By contrast, the same substantive message may look different if it appears in a sales deck delivered to customers whose use practices the claim, or in a field script for accounts selected because they perform the patented method.

Discovery should therefore ask not simply “what was said?” but “who was supposed to hear it?”

Useful evidence includes customer segmentation, target-account lists, prescriber deciles, use-case classifications, vertical-market plans, account notes, distributor territories, implementation pipelines, formulary strategy, and sales compensation metrics. If the defendant defined a target audience by reference to the infringing use and then armed personnel with a message for that audience, the inducement theory becomes much more concrete.

Public Materials Still Matter, But Usually as Part of a Path

Hikma should not cause plaintiffs to abandon public materials. It should cause them to use public materials more carefully. Public materials can help show consistency between external messaging and internal strategy. They can supply the language that sales teams were trained to amplify. They can identify the intended audience. They can show that the defendant voluntarily chose a broad therapeutic, technical, or application category when a narrower lawful description was available. They can corroborate recipient testimony.

But public materials become weak when the theory depends on inference stacking. A court is unlikely to be impressed by a theory that requires the recipient to find a generalized statement, know background market facts, infer the patented use, and then treat the statement as a prompt to infringe. The stronger path is shorter: defendant message, relevant audience, claim-linked use, action.

When Has the Evidence Crossed the Threshold?

There is no clean formula, and Hikma does not supply one. But the practical threshold is crossed when the plaintiff can tell a coherent inducement story without relying on a long chain of speculation. The strongest cases usually have five features.

First, there is a defendant-originated affirmative act. The act may be a statement, instruction, training, sales strategy, technical guidance, reimbursement push, customer presentation, or coordinated course of conduct. But it must be something more than silence, product availability, or passive awareness.

Second, the act is tied to the patented method, not merely the accused product. If the same evidence would exist regardless of the patented use, it may prove product promotion but not inducement.

Third, the act is directed to an audience that performs, controls, or materially influences the infringing steps. The closer the audience is to the direct infringement, the stronger the evidence.

Fourth, the message is clear enough to the audience without excessive inference. It need not use the patent’s words. It need not be express. But the connection to the infringing use should be practical and understandable in context.

Fifth, the plaintiff can address innocent explanations. Required labeling, standard industry terminology, compatibility statements, truthful equivalence language, safety warnings, and routine commercial announcements may all have lawful explanations.

The plaintiff needs evidence showing why the challenged conduct is different. A useful test is this: can you describe the inducement theory in one sentence without using “would have known,” “could have understood,” or “must have intended”? For example: “The defendant trained its sales force to target customers using the claimed configuration and supplied a presentation instructing those customers how to achieve the claimed operating mode.” That is a materially stronger theory than: “The defendant sold a compatible product and knew customers would use it in an infringing way.”

Circumstantial Evidence Can Still Be Enough

One risk after Hikma is overcorrection. Defendants will argue that anything short of an express instruction is insufficient. That is not what the decision says. Circumstantial evidence can still prove inducement. A coordinated pattern may do the work that no single document does. For example, evidence that the defendant identified the patented use as a revenue opportunity, trained personnel on how to approach that use, targeted customers who perform that use, supplied technical or commercial materials tied to that use, and tracked resulting conversions may support inducement even without an express instruction to infringe.

The key is coherence. The evidence must show a course of conduct that makes the infringing use the intended destination, not merely a foreseeable stop along the way.

Defense Lessons

For defendants, Hikma provides a useful vocabulary for narrowing inducement cases.

The defense should force the plaintiff to identify the affirmative act, the relevant audience, the claim limitation, and the evidentiary link between the act and the direct infringement. It should separate knowledge from encouragement. It should identify lawful explanations for challenged conduct. It should distinguish product promotion from method promotion. It should test whether the alleged inducement reached anyone who actually performed or caused the infringing steps.

At the same time, defendants should not assume that formal compliance is enough. A clean label, careful public language, or general product messaging may not protect a defendant if internal documents or field conduct show a deliberate campaign to drive the carved-out, restricted, or patented use. The post-Hikma defense is strongest when the lawful explanation holds not only on paper, but also in the field.

The Takeaway

Hikma does not eliminate inducement claims. It makes them more disciplined.

For plaintiffs, the task is to move from market inevitability to defendant-directed conduct. For defendants, the task is to keep the case framed as lawful product distribution, customer choice, or regulatory compliance. The fight will often turn on whether the plaintiff can connect three things: a claim limitation, a targeted audience, and a defendant-originated message or course of conduct that affirmatively pushes the audience toward the patented method.

That is where discovery should be aimed from the beginning. Not at proving that infringement was predictable. At proving that the defendant tried to make it happen.